Fig. 3From: Severe colitis after PD-1 blockade with nivolumab in advanced melanoma patients: potential role of Th1-dominant immune response in immune-related adverse events: two case reportsTemporal changes in white blood cell counts, serum C-reactive protein levels, and blood cytokine levels (IL-6, IL-17, IFN-γ, and TNF-α)Back to article page